NMRA Stock — Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. (NMRA)

Updated October 16, 2026.

NMRA is a Stock. Total return is -97.2% over the past 3.1 years, 173.6 points behind SPY at 76.4%.

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases, with its lead candidate navacaprant in phase 3 trials for major depressive disorder and several other programs across schizophrenia, dementia, Parkinson's disease, and other neurological conditions. The company does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to early-stage drug development in the neurology and psychiatry space.

NMRA performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.2% over the past 3.1 years, 173.6 points behind SPY at 76.4%. Over the past year its total return — price change plus distributions reinvested — is -73.4%. Its deepest 1-year drawdown was 90.1%.

NMRA key facts

Asset type

Stock

Asset class

Equity

Inception date

09/14/2023

Distribution frequency

None

Last close

$0.47 (as of 2026-10-16)

Market cap

$89,062,662

Average volume

3472300.0

Beta

2.975

Payout ratio

0.0%

EPS

$-1.23

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NMRA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 90.1%.

Who may consider NMRA — and who may not

It is a weaker fit for investors who need monthly cash flow (NMRA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NMRA

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions